WGU D345: PSYCHOPHARMACOLOGY 2026/2027 | 100% VERIFIED EXAM QUESTIONS AND
EXPLAINED ANSWERS | LATEST WESTERN GOVERNORS UNIVERSITY OBJECTIVE
ASSESSMENT | NEWEST
1. What term describes the study of drug movement through the body,
including absorption, distribution, metabolism, and excretion?
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacogenomics
D. Pharmacotherapeutics
✓ CORRECT ANSWER: B. Pharmacokinetics
Rationale: Pharmacokinetics examines how the body handles a drug over
time — absorption, distribution, metabolism, and excretion (ADME).
2. Which route of drug administration bypasses first-pass metabolism?
A. Oral
B. Rectal
C. Intravenous
D. Sublingual
✓ CORRECT ANSWER: C. Intravenous
Rationale: IV administration delivers the drug directly into systemic
circulation, completely bypassing hepatic first-pass metabolism.
3. The volume of distribution (Vd) reflects:
A. The rate at which a drug is cleared by the kidneys
B. How extensively a drug distributes into body tissues
C. The percentage of drug bound to plasma proteins
D. The half-life of a drug in plasma
✓ CORRECT ANSWER: B. How extensively a drug distributes into body
tissues
Rationale: A high Vd indicates wide tissue distribution; a low Vd suggests the
drug stays mostly in the bloodstream.
D345 Psychopharmacology OA — Page 1 of 94
,4. First-pass metabolism primarily occurs in the:
A. Kidney
B. Lungs
C. Liver
D. Small intestine
✓ CORRECT ANSWER: C. Liver
Rationale: After oral ingestion, drugs absorbed from the GI tract travel via the
portal vein to the liver, where significant metabolism can occur before
systemic circulation.
5. Drug half-life (t½) is defined as:
A. Time for peak plasma concentration
B. Time for the drug to reach steady state
C. Time for plasma drug concentration to decrease by 50%
D. Duration of therapeutic effect
✓ CORRECT ANSWER: C. Time for plasma drug concentration to
decrease by 50%
Rationale: t½ determines dosing intervals and time to steady state
(approximately 4–5 half-lives).
6. Steady-state plasma concentration is typically reached after
approximately:
A. 1 half-life
B. 2 half-lives
C. 4–5 half-lives
D. 10 half-lives
✓ CORRECT ANSWER: C. 4–5 half-lives
Rationale: After 4–5 half-lives, the rate of drug intake equals the rate of
elimination, achieving steady state.
7. Which cytochrome P450 enzyme is responsible for metabolizing the
majority of psychiatric medications?
A. CYP1A2
B. CYP2D6
D345 Psychopharmacology OA — Page 2 of 94
, C. CYP3A4
D. CYP2C19
✓ CORRECT ANSWER: C. CYP3A4
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, including
many psychiatric agents such as benzodiazepines and antidepressants.
8. A patient is a CYP2D6 poor metabolizer. What is the expected effect on a
drug primarily metabolized by CYP2D6?
A. Faster drug clearance
B. Lower plasma drug levels
C. Higher plasma drug levels and increased side effects
D. No clinical effect
✓ CORRECT ANSWER: C. Higher plasma drug levels and increased side
effects
Rationale: Poor metabolizers lack adequate enzyme activity, so the drug
accumulates, leading to higher levels and potential toxicity.
9. Bioavailability refers to:
A. The concentration of drug in the urine
B. The fraction of administered drug that reaches systemic circulation
unchanged
C. The volume in which a drug distributes
D. The rate of protein binding
✓ CORRECT ANSWER: B. The fraction of administered drug that reaches
systemic circulation unchanged
Rationale: An IV dose has 100% bioavailability; oral bioavailability is reduced
by first-pass metabolism and incomplete absorption.
10. Which process describes the movement of a drug from a region of high
concentration to low concentration across a membrane?
A. Active transport
B. Facilitated diffusion
C. Passive diffusion
D. Endocytosis
✓ CORRECT ANSWER: C. Passive diffusion
D345 Psychopharmacology OA — Page 3 of 94
, Rationale: Most drugs cross cell membranes by passive diffusion, driven by
concentration gradient without energy expenditure.
11. Pharmacodynamics is best defined as:
A. How the body affects a drug
B. How a drug affects the body
C. Drug distribution into tissues
D. Drug excretion by the kidneys
✓ CORRECT ANSWER: B. How a drug affects the body
Rationale: Pharmacodynamics studies the biochemical and physiological
effects of drugs and their mechanisms of action.
12. The therapeutic index (TI) is the ratio of:
A. Effective dose to bioavailability
B. Toxic dose to effective dose
C. Half-life to volume of distribution
D. Protein binding to renal clearance
✓ CORRECT ANSWER: B. Toxic dose to effective dose
Rationale: TI = TD50/ED50. A narrow TI (e.g., lithium) means there is little
difference between therapeutic and toxic doses.
13. Lithium has a narrow therapeutic index. This means:
A. It is only effective at high doses
B. The difference between effective and toxic doses is small
C. It distributes widely into fat tissue
D. It is rapidly metabolized by the liver
✓ CORRECT ANSWER: B. The difference between effective and toxic
doses is small
Rationale: Lithium's narrow TI requires frequent serum level monitoring to
avoid toxicity.
14. Which pharmacokinetic parameter is most affected by liver disease?
A. Renal clearance
B. Volume of distribution
D345 Psychopharmacology OA — Page 4 of 94
EXPLAINED ANSWERS | LATEST WESTERN GOVERNORS UNIVERSITY OBJECTIVE
ASSESSMENT | NEWEST
1. What term describes the study of drug movement through the body,
including absorption, distribution, metabolism, and excretion?
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacogenomics
D. Pharmacotherapeutics
✓ CORRECT ANSWER: B. Pharmacokinetics
Rationale: Pharmacokinetics examines how the body handles a drug over
time — absorption, distribution, metabolism, and excretion (ADME).
2. Which route of drug administration bypasses first-pass metabolism?
A. Oral
B. Rectal
C. Intravenous
D. Sublingual
✓ CORRECT ANSWER: C. Intravenous
Rationale: IV administration delivers the drug directly into systemic
circulation, completely bypassing hepatic first-pass metabolism.
3. The volume of distribution (Vd) reflects:
A. The rate at which a drug is cleared by the kidneys
B. How extensively a drug distributes into body tissues
C. The percentage of drug bound to plasma proteins
D. The half-life of a drug in plasma
✓ CORRECT ANSWER: B. How extensively a drug distributes into body
tissues
Rationale: A high Vd indicates wide tissue distribution; a low Vd suggests the
drug stays mostly in the bloodstream.
D345 Psychopharmacology OA — Page 1 of 94
,4. First-pass metabolism primarily occurs in the:
A. Kidney
B. Lungs
C. Liver
D. Small intestine
✓ CORRECT ANSWER: C. Liver
Rationale: After oral ingestion, drugs absorbed from the GI tract travel via the
portal vein to the liver, where significant metabolism can occur before
systemic circulation.
5. Drug half-life (t½) is defined as:
A. Time for peak plasma concentration
B. Time for the drug to reach steady state
C. Time for plasma drug concentration to decrease by 50%
D. Duration of therapeutic effect
✓ CORRECT ANSWER: C. Time for plasma drug concentration to
decrease by 50%
Rationale: t½ determines dosing intervals and time to steady state
(approximately 4–5 half-lives).
6. Steady-state plasma concentration is typically reached after
approximately:
A. 1 half-life
B. 2 half-lives
C. 4–5 half-lives
D. 10 half-lives
✓ CORRECT ANSWER: C. 4–5 half-lives
Rationale: After 4–5 half-lives, the rate of drug intake equals the rate of
elimination, achieving steady state.
7. Which cytochrome P450 enzyme is responsible for metabolizing the
majority of psychiatric medications?
A. CYP1A2
B. CYP2D6
D345 Psychopharmacology OA — Page 2 of 94
, C. CYP3A4
D. CYP2C19
✓ CORRECT ANSWER: C. CYP3A4
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, including
many psychiatric agents such as benzodiazepines and antidepressants.
8. A patient is a CYP2D6 poor metabolizer. What is the expected effect on a
drug primarily metabolized by CYP2D6?
A. Faster drug clearance
B. Lower plasma drug levels
C. Higher plasma drug levels and increased side effects
D. No clinical effect
✓ CORRECT ANSWER: C. Higher plasma drug levels and increased side
effects
Rationale: Poor metabolizers lack adequate enzyme activity, so the drug
accumulates, leading to higher levels and potential toxicity.
9. Bioavailability refers to:
A. The concentration of drug in the urine
B. The fraction of administered drug that reaches systemic circulation
unchanged
C. The volume in which a drug distributes
D. The rate of protein binding
✓ CORRECT ANSWER: B. The fraction of administered drug that reaches
systemic circulation unchanged
Rationale: An IV dose has 100% bioavailability; oral bioavailability is reduced
by first-pass metabolism and incomplete absorption.
10. Which process describes the movement of a drug from a region of high
concentration to low concentration across a membrane?
A. Active transport
B. Facilitated diffusion
C. Passive diffusion
D. Endocytosis
✓ CORRECT ANSWER: C. Passive diffusion
D345 Psychopharmacology OA — Page 3 of 94
, Rationale: Most drugs cross cell membranes by passive diffusion, driven by
concentration gradient without energy expenditure.
11. Pharmacodynamics is best defined as:
A. How the body affects a drug
B. How a drug affects the body
C. Drug distribution into tissues
D. Drug excretion by the kidneys
✓ CORRECT ANSWER: B. How a drug affects the body
Rationale: Pharmacodynamics studies the biochemical and physiological
effects of drugs and their mechanisms of action.
12. The therapeutic index (TI) is the ratio of:
A. Effective dose to bioavailability
B. Toxic dose to effective dose
C. Half-life to volume of distribution
D. Protein binding to renal clearance
✓ CORRECT ANSWER: B. Toxic dose to effective dose
Rationale: TI = TD50/ED50. A narrow TI (e.g., lithium) means there is little
difference between therapeutic and toxic doses.
13. Lithium has a narrow therapeutic index. This means:
A. It is only effective at high doses
B. The difference between effective and toxic doses is small
C. It distributes widely into fat tissue
D. It is rapidly metabolized by the liver
✓ CORRECT ANSWER: B. The difference between effective and toxic
doses is small
Rationale: Lithium's narrow TI requires frequent serum level monitoring to
avoid toxicity.
14. Which pharmacokinetic parameter is most affected by liver disease?
A. Renal clearance
B. Volume of distribution
D345 Psychopharmacology OA — Page 4 of 94
